Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - lercanidipine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; povidone; magnesium stearate; hypromellose; purified talc; titanium dioxide; macrogol 6000; iron oxide red - lercan is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - lercanidipine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; hypromellose; purified talc; titanium dioxide; macrogol 6000; iron oxide yellow - lercan is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide yellow; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: iron oxide red; iron oxide yellow; croscarmellose sodium; silicon dioxide; carnauba wax; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 3350; iron oxide black - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - gabapentin - tablet, film coated - excipient ingredients: hyprolose; mannitol; crospovidone; purified talc; magnesium stearate; poloxamer; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - gabaran is indicated for the maintenance treatment of, partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabaran is also indicated for the maintenance treatment of neuropathic pain